Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allarity Therapeutics, Inc. - Common stock
(NQ:
ALLR
)
0.1829
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Allarity Therapeutics, Inc. - Common stock
< Previous
1
2
Next >
ALLARITY THERAPEUTICS, INC. ANNOUNCEMENT: If You Have Suffered Losses in Allarity Therapeutics, Inc. (NASDAQ: ALLR), You Are to Contact The Rosen Law Firm About Your Rights
August 20, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 05, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 30, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Allarity Therapeutics Inc. (NASDAQ: ALLR) Near the Top of Equities by Percentage Gain on 4/12
April 12, 2024
Via
Investor Brand Network
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 30, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Continues Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 29, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 28, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
July 26, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
July 24, 2024
From
The Schall Law Firm
Via
Business Wire
Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALLR
July 24, 2024
From
Rosen Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 24, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 24, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
July 24, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 23, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
July 22, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
June 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 07, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 06, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
May 02, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
April 17, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
April 04, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
March 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
March 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
March 08, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics to Present at Biomarkers 2024
February 28, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
December 12, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.